About Us

Our team is committed to enhancing our understanding of human disease.

Technology

Transforming the measurement of disease progression in vivo using noninvasive biosensors.

Pipeline

Bioengineered, tunable sensors that are designed for each protease-mediated disease.

Partners

Evolving the way diseases are understood, tracked and treated to accelerate the development of drugs.

News & Events

Transforming the way diseases are detected, tracked, treated, and understood.

Careers

Leveraging the profound advances in engineering, medicine, biotechnology, and machine learning.

Contact Us

We are proud to be members of the pre-eminent Cambridge biotech community.

News & Events

Transforming the way diseases are detected, tracked, treated, and understood.

Press Releases

  1. February 2, 2021

    Glympse Bio Names Jessica Atkinson Senior Vice President of Business Development
  2. November 13, 2020

    First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual Meeting
  3. November 10, 2020

    Glympse Bio to Present Clinical Data at the AASLD 2020 Annual Meeting
  4. July 15, 2020

    Glympse Bio Announces $46.7 Million Series B Financing
  5. November 8, 2019

    Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management
  6. November 4, 2019

    Glympse Bio, Inc. Names Tracey Dawson as Chief Commercial Officer and Head of Strategy
  7. October 28, 2019

    Gilead and Glympse Bio Announce Strategic Collaboration For Use of Biomarker Technology in NASH Clinical Development

  8. August 1, 2019

    Pharmaceutical Executive Francis Cuss Joins Glympse Bio Board
  9. May 14, 2019

    Glympse Bio, Inc. Names Wendy Winckler as Chief Scientific Officer
  10. February 11, 2019

    Glympse Bio, Inc. Named to FierceMedTech’s “Fierce 15”
  11. December 4, 2018

    Glympse Bio, Inc. Appoints Caroline J. Loew, Ph.D. President and Chief Executive Officer
  12. October 3, 2018

    Glympse Bio, Inc. Raises $22m Series A Financing
More

News

  1. Med Tech Gurus

    Fit For Purpose with Caroline Loew Ph.D.
  2. Biotech2050

    Noninvasive diagnostics for NASH and inflammatory indications, Caroline Loew, CEO, Glympse Bio
  3. MIT News

    Faster tracking of treatment responses
  4. Health Professional Radio

    Tunable Biosensors for Noninvasive Disease Monitoring
  5. BioSpace

    Glympse Advances BioSensors for NASH and Other Protease-Mediated Diseases
  6. Decision Resource Group

    How Glympse Bio oversubscribed their Series B funding amidst the pandemic
  7. Fierce MedTech

    Glympse Bio clears first-in-human safety study of its injectable biosensors
  8. BioSpace

    On the Heels of $46.7 Million Financing, Glympse Bio Announces Positive Data for NASH Sensors
  9. MedTech Intelligence

    Advancing the Biopsy: Biosensors as a More Accurate and Sensitive Disease State Diagnostic Tool
  10. BioProcess Online

    Biosensors & Big Data: Implications For Biologics Developers
  11. 360Dx

    Glympse Bio Platform Enters Trials for Liver Disease Diagnosis, Treatment Monitoring
  12. STAT+

    Startup Spotlight: Glympse Bio hopes its test will show whether drugs are actually working
  13. ENDPOINTS News

    Gilead-partnered Glympse snares $46.7M for their NASH-snooping biosensors
  14. BioCentury

    Glympse raises $47.6M to test biosensors that could improve on liver biopsies in NASH
  15. MedCity News

    Glympse Bio raises more than $46M in Series B round for biosensor technology
  16. FierceBiotech

    Glympse Bio secures $46M to boost its injectable diagnostics for NASH, cancer & more
  17. The Wall Street Journal | Dow Jones

    Glympse Bio Raises $46.7 Million in Series B Funding Round
  18. BioWorld MedTech

    Glympse Bio snags $46.7M to advance biosensor platform
  19. BioSpace

    Glympse Bio Secures $46.7 Million to Advance NASH Biosensor Program
  20. 360Dx

    Glympse Bio Closes $46.7M Series B Financing
  21. FierceBiotech

    Glympse Bio, Inc. Named to FierceMedTech’s “Fierce 15”
  22. Youtube

    Sangeeta Bhatia Speaks at the 2018 National Academy of Sciences Meeting

  23. MIT News

    New Technology Can Detect Tiny Ovarian Tumors
  24. NAS

    Sangeeta Bhatia Inducted into the National Academy of Sciences (NAS)
  25. Xconomy

    Sangeeta Bhatia Winner of the "Innovation at the Intersection" Xconomy Award
  26. Georgia Tech

    Gabe Kwong Receives NIH Director’s New Innovator Award
  27. MIT News

    Nanosensors Could Help Determine Tumors’ Ability to Remodel Tissue
  28. Scientific American

    LEGO Dr. Bhatia
  29. MIT News

    A Paper Diagnostic for Cancer
  30. MIT News

    Finding Blood Clots Before They Wreak Havoc
  31. YouTube

    New Nanoparticle Detects Harmful Blood Clots (Video)
  32. MIT News

    New Technology May Enable Earlier Cancer Diagnosis
More

Publications

  1. Hepatic Protease Gene Expression Analysis to Predict Advanced Fibrosis in Patients with NASH: a Cross-validation Study

    Cazanave, S, Pacula, M, Huang, E, Kwong, G, Luther, J, Chung, R, Corey, K, Daly, A, Anstee, Q, Govaere, O, Winckler, W

  2. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease

    Kwong, GA, von Maltzahn, G, Murugappan, G, Abudayyeh, O, Mo, S, Papayannopoulos, IA, Sverdlov, DY, Liu, SB, Warren, AD, Popov, Y, Schuppan, and Bhatia, SN (2012): Nature Biotechnology. 1: 63-70.

  3. Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis

    Lin KY, Kwong GA, Warren AD, Wood DK, Bhatia SN (2013): ACS Nano. 7(10): 9001-9009.

  4. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics

    Warren, AD†, Kwong, GA†, Wood, DK†, Lin, KY, and Bhatia, SN (2014): PNAS. 111(10): 3671-3676.

  5. Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers

    Warren, AD†, Gaylord, ST†, Ngan, KC, Milutinovic, MD, Kwong, GA, Bhatia, SN‡, and Walt, DR‡ (2014): JACS. 136(39): 13709-13714.

  6. Mathematical framework for activity-based cancer biomarkers

    Kwong, GA, Dudani, JS, Carrodeguas, E, Mazumdar, EV, Zekavat, SM, and Bhatia, SN (2015): PNAS. 112(41): 12627-12632.

  7. Photoactivated spatiotemporally-responsive nanosensors of in vivo protease activity

    Dudani, JS, Jain, PK, Kwong, GA, Stevens, KR, and Bhatia, SN (2015): ACS Nano. 9(12): 11708-11717

  8. Sustained-release synthetic biomarkers for monitoring thrombosis and inflammation using point-of-care compatible readouts

    Dudani, JS, Buss, CG, Akana, RT, Kwong, GA, and Bhatia, SN (2016): Advanced Functional Materials. 26(17): 2919-2928

  9. Magnetically actuated protease sensors for in vivo tumor profiling

    Schuerle, S, Dudani, JS, Christiansen, MG, Anikeeva, P, and Bhatia, SN (2016): Nano Letters. 16(10): 6303-6310

  10. Ultrasensitive tumour-penetrating nanosensors of protease activity

    Kwon, EJ, Dudani, JS, and Bhatia, SN (2017): Nature Biomedical Engineering. 1. 54.

  11. Classification of prostate cancer using a protease activity nanosensor library

    Dudani. JS, Ibrahima M, Kirkpatrick J, Warren A, and Bhatia SN (2018): PNAS. 10.1073

  12. Glympse Liver Test for Noninvasive Monitoring of Combination Drug Therapy in a Rat Model of Nonalcoholic Steatohepatitis (NASH)

    Sophie Cazanave, Maciej Pacula, Anna Zagorska, Andrew Warren, Sarah Sherman, Eric Huang, Katie Walker, Kathy Liu, David Lopez, David Newstrom, Shiva Zaboli, Jamie Bates, John T Liles,Grant R Budas, David G Breckenridge, Andrew Billin, Gabriel A. Kwong (2019): Presented at AASLD 2019
More

Events

No new events at this time.

Social Media

GlympseBioGlympse Bio@GlympseBio·
14 Apr

#GlympseBio CEO @CarolineLoew recently joined the @MedTechGurus podcast to discuss her strategic approach to fundraising, her “fit for purpose” model for developing new technologies, and all things #medtech

Listen: https://med-tech-gurus.libsyn.com/fit-for-purpose-with-fit-for-purpose

Twitter 1382375654998618112
GlympseBioGlympse Bio@GlympseBio·
22 Mar

#GlympseBio CEO @CarolineLoew recently joined @rahulc and @aloktayi on the @Biotech2050Pod to discuss #drugdevelopment, our #biosensor platform, and her career in the #lifescience industry.

Listen now: https://soundcloud.com/user-306573075/50-noninvasive-diagnostics-for-nash-and-inflammatory-indications-caroline-loew-ceo-glympse-bio

Twitter 1374107299485253637
GlympseBioGlympse Bio@GlympseBio·
10 Feb

#ICYMI – CEO Dr. Caroline Loew shares career advice for moving from pharma to #biotech, discusses our response to the pandemic, and outlines our clinical programs with @BioPharmaMike on @DRGInsights’ “Conversations in Healthcare.”

Watch: https://decisionresourcesgroup.com/downloads/glympse-bio-oversubscribed-series-b-funding-amidst-pandemic/

Twitter 1359541385544798210
GlympseBioGlympse Bio@GlympseBio·
8 Feb

#GlympseBio CEO @CarolineLoew and co-founder @SNBhatia recently spoke with @MIT News about the discovery that led to our platform of synthetic #biosensors and their journey from concept to company.

Read: https://news.mit.edu/2021/faster-tracking-treatment-responses-glympse-bio-0202

Twitter 1358783699052027905